BioSpace News Archive

Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Sujal Shah, Chief Executive Officer of CymaBay Therapeutics , to its Board of Directors.

12-month results from the PRESTIGE* Below-the-Knee (BTK) study have been presented as a Late Breaking Trial at LINC 2021.

SkinCeuticals, the #1 medical professional skincare brand in the US, announces the opening of SkinCeuticals SkinLab™ in partnership with Cosmetic Surgery Institute (CSI).

In an effort to expedite care for coronavirus disease 2019 patients upon hospital admission, a team at The Feinstein Institutes for Medical Research has developed a machine learning artificial intelligence powered clinical predictive tool that can accurately assess patients for the risk of respiratory failure within 48 hours.

Biosenta Inc. (“Biosenta” or the “Company”) listed on the CSE (CSE:ZRO) announces that it will enter into a series of prime plus 5% unsecured promissory notes (the “Notes”) in consideration for cash investments in the aggregate amount of $85,000 (together, the “Investment”).

On Tuesday, January 26th, Governor Andy Beshear’s office announced that the first two cases of a more contagious variant of coronavirus, first identified in the United Kingdom, have been confirmed in Kentucky.

Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and a National Cancer Institute- designated Comprehensive Cancer Center, together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (

Growing population and prevalent unhealthy eating habits have driven nutrigenomics testing market trends substantially over the past few years.

A pet diabetes care devices market player, Trividia Health, has recently released Test Buddy, a pet-monitoring blood glucose system developed for helping cats and dogs living with diabetes.

The influx of the latest technologies and the spike in the number of birth rates worldwide will influence point of care ultrasound market trends over the coming years.